Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Aldosterone synthase inhibitors
9 evidence topics · 11 sources
Class: a new mechanism developed to treat hypertension
Baxdrostat (BAXFENDY): the first approved aldosterone synthase inhibitor
Baxdrostat: BaxHTN, uncontrolled or resistant hypertension
“This multinational, randomized, double-blind, placebo-controlled phase 3 trial recruited participants with seated office systolic blood pressure (seated-SBP) ≥140 mmHg and <170 mmHg, despite stable treatment with 2 (uncontrolled hypertension) or ≥3 (resistant hypertension) antihypertensive medications, including a diuretic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 12, change from baseline in least-squares mean seated-SBP for baxdrostat 1mg was –14.5 mmHg (95% confidence interval [CI], –16.5 to –12.5); baxdrostat 2mg, –15.7 mmHg (–17.6 to –13.7); versus placebo, –5.8 mmHg (–7.9 to –3.8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baxdrostat: Bax24, resistant hypertension
“Following a 2-week placebo run-in period, patients with 24 h ambulatory SBP ≥130 mm Hg were randomly assigned (1:1) to receive 2 mg baxdrostat or placebo orally once daily for 12 weeks, in addition to background therapy (stratified by baseline ambulatory SBP <140 mm Hg or ≥140 mm Hg).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Baxdrostat significantly reduced 24 h ambulatory SBP versus placebo in patients with resistant hypertension, providing further evidence of the potential of aldosterone synthase inhibition for treatment of hard-to-control hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Baxdrostat: chronic kidney disease with uncontrolled hypertension
Lorundrostat: investigational aldosterone synthase inhibitor under FDA review
Vicadrostat: investigational, without a hypertension trial in its phase 3 set
Class effect on blood pressure and electrolytes across randomized trials
“ASI reduced systolic blood pressure (SBP) (MD: –6.7 mm Hg; CrI: −8.78, −4.59; τ2 3.24), diastolic blood pressure (MD: -2.09 mm Hg; CrI: −3.68, −0.44; τ2 1.44), and hypertensive urgency (OR: 0.36; CrI: 0.13, 0.90; τ2 0.07) compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second-generation ASIs had a high likelihood of a clinically significant reduction in SBP compared with placebo. However, hyperkalemia, hyponatremia, and hypotension were more frequent with ASIs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote